deferiprone has been researched along with Hepatitis C in 4 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major." | 3.73 | Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, AC | 1 |
| Peng, CT | 2 |
| Wu, SF | 2 |
| Wu, KH | 2 |
| Chiang, IP | 1 |
| Tsai, CH | 2 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| Lindeman, R | 1 |
| Töndury, P | 1 |
| Zimmermann, A | 1 |
| Nielsen, P | 1 |
| Hirt, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients[NCT00349453] | Phase 2 | 24 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for deferiprone and Hepatitis C
| Article | Year |
|---|---|
Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
Topics: Adolescent; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Chelatio | 2006 |
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch | 2006 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chronic Disease; Deferiprone; Ferritins; Hepatitis C; Humans; I | 1998 |